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INTRODUCTION 
Rhabdomyosarcoma (rhabdos, “rod”, mys , “muscle”, sarkos, “flesh” ) is a primary 
solid malignant tumor in children and adolescents that arises from the embryonic 
mesenchyme with the potential to differentiate into skeletal muscle  (1). Because 
of its mesenchymal origin, it can arise in tissue that does not normally contain 
skeletal muscle (urinary bladder, bile ducts) (2). 
 
The incidence of pediatric soft tissue sarcoma (STS) in Germany is 1:100 000 
children (3). Comprising over 50% of all soft tissue sarcoma (STS) in children, 
rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma (0.5:100 000 
in patients < 15 years) and the third most common extracranial solid tumor in 
children after neuroblastoma and Wilms tumor, accounting for approximately 5% 
of all pediatric cancers (1, 4, 5). Boys and girls seem to be equally affected by 
RMS (sex ratio 1.1:1 boys vs. girls) with a peak incidence in early childhood. The 
median age at diagnosis is approximately 5 years (6). 
   
Classification 
The classification of RMS is based on histological criteria and is of critical 
importance regarding the prognosis of patients. Mainly, there are two subtypes: 
embryonal and alveolar (7, 8).  
 
Alveolar RMS (RMA) occurs in approximately 20% of all cases and, due to its 
high predilection of spread to regional lymph nodes, it is commonly associated 
with a poor prognosis (9). Genetically, RMA is consistently associated with two 
reciprocal translocations. The most common of them (55%) t(2;13)(q35;q14) fuses 
the DNA binding domain of PAX3 with the regulatory domain of FKHR (FOXO1) 
and occurs more frequently in older patients, who have a worse outcome (10). The 
other variant t(1;13)(p36;q14) fuses the PAX7 gene with FKHR(FOXO1) and 
occurs more often in infants, who have a better prognosis (11). The result of these 
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translocations is an increase of PAX activity leading to the de-differentiation and 
proliferation of myogenic cells.   
 
However, 20-25% of RMA lack these translocations (4, 12, 13). They represent a 
heterogenous group of tumors with alternate fusions, fusions without production of 
detectable RNA, tumors with only rare fusion-positive cells and those with no 
molecular evidence of fusion. The latter category constitutes the bulk of this group 
(14-16). 
  
Williamson et al analyzed the fusion gene status of 210 RMS specimens, dividing 
them into three groups: RME, RMA fusion gene positive (RMAp) and RMA fusion 
gene negative (RMAn). Through analysis of clinical data and genomic profiling 
they were able to demonstrate that RMAn is practically indistinguishable from 
RME in terms of clinical presentation, outcome and molecular biology. Moreover, 
using array based comparative genomic hybridization (aCGH), they showed that 
the frequency of many specific amplifications and gains is significantly different in 
RMAp compared to RMAn and RME. For example, MYCN amplification was found 
to be present in 20% of all RMAp patients, in 4% of RME and in none of the 
RMAn. Additionally, aCGH analysis showed that gain of chromosome 8 occurred 
in 74% of RME samples, 55% of RMAn samples and none of RMAp samples (17).  
 
These data support previous studies by Wachtel and Davicioni. Wachtel et al 
reported the consistent high expression of AP2ß and P-cadherin protein in RMAp 
specimens and endothelial growth factor receptor (EGFR) and fibrillin-2 in RME, 
while RMAn was shown to lack the expression of AP2ß and P-cadherin and to 
have levels of  EGFR and fibrillin-2 intermediate between those of RMAp and RME 
(18). Davicioni et al did not show any signature distinguishing RMAn tumors from 
RME in their expression and loss of heterogeneity analysis (13).  
Despite consensus among the authors of the above mentioned studies, there is an 
ongoing debate about how or as to even if molecular biology should be integrated 
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into the existing risk protocols (19-21). The integration of molecular biology into the 
risk stratification systems may result in a more precise classification of the patients 
and a better tailoring of the therapeutic regimen without compromising their 
survival.    
 
The embryonal RMS (RME) occurs in approximately 65-70% of the cases. These 
patients have a better prognosis compared with those suffering from RMA. RME 
rarely spreads to regional lymph nodes. Genetically, no consistent molecular 
markers have been associated with RME, although there is a loss of 
heterozygosity (LOH) at the 11p15 in up to 80% of the cases (22). The LOH at this 
site has also been observed to induce an increased expression of IGF II, as the 
gene which encodes this factor lies also within this locus, thus possibly playing an 
important role in tumor growth (22). 
Risk stratification  
The risk stratification system has been developed to tailor the intensity of therapy 
to patient outcomes.  
According to the CWS Guidance (Cooperative Weichteilsarkom Study) of the 
German Society of Pediatric Oncology and Hematology (Gesellschaft für 
Pädiatrische Onkoloige und Hämatologie – GPOH), the patients suffering from 
RMS are divided in 8 subgroups (A-H) which are subsequently assigned to one of 
the 4 categories of risk: low, standard, high and very high, based on postsurgical 
stage (Table I), histology, localization of the tumor, lymph node status, tumor size 
and patient’s age (Table 2). This system is based on the results obtained from the 
CWS-96 trials (23, 24).  
 
The low-risk group is defined by favorable histology, IRS stage I, no lymph node 
involvement, patient’s age < 10 years and tumor size < 5 cm. It represents a group 
of patients accounting for 6-8% of the whole population of children suffering from 
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RMS.  Most of these patients suffer from localized paratesticular RMS and have 
an excellent outcome (6). 
 
The standard risk group is generally defined by favorable histology, IRS group I-
III, no lymph node involvement, independent of patient’s age and tumor size.  The 
patients assigned to the subgroup B are similar to the ones from the low-risk 
group but have large tumors (>5cm) and are older than 10 years of age.  In 
subgroup C are included the children with orbital, head and neck non-
parameningeal RMS. To subgroup D are assigned the patients younger than 10 
years of age having small tumors (< 5 cm) with favorable histology (RME) arising 
in the extremities, parameningeal sites and bladder-prostate (6).   
  
In the high-risk group, patients > 10 years of age with tumors > 5 cm, 
unfavorable location but with favorable histology, IRS group II-III and no lymph 
node involvement are included. The patients with embryonal N1 tumors are also 
included in this group. 
 
The patients with tumors of unfavorable histology, IRS group II-III and positive 
lymph nodes are considered at very high-risk of tumor recurrence (6).      
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IRS group Definition 
I R0 resection of a localized primary tumor, without lymph node 
involvement 
II R1 resection of a localized primary tumor, with R0 or R1 resection 
of the involved lymph nodes 
III R2 resection of a localized primary tumor 
IV Distant metastases 
 
Table 1. Postsurgical stage (IRS group)  according to STSC (Soft Tissue Sarcoma Committee) 
 
R0 resection: microscopically complete resection 
R1 resection: macroscopically complete resection with microscopic residuals   
R2 resection: macroscopic tumor rests  
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Risk 
group 
Subgroup Histology IRS group 
(postsurgical 
stage) 
Localization Lymph 
node 
status 
Tumor 
size 
Patient’s 
age 
Low risk A Favorable I Any N0 <5 cm <10 
years 
 
Standard 
risk 
B Favorable I Any N0 >5 cm > 10 
years 
C Favorable II, III Favorable N0 Any Any 
D Favorable II, III Unfavorable N0 <5 cm <10 
years 
 
High risk 
E Favorable II, III Unfavorable N0 >5 cm >10 
years 
F Favorable II, III Any N1 Any Any 
G Unfavorable I, II, III Any N0 Any Any 
Very 
high risk 
H Unfavorable II, III Any N1 Any Any 
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Histology Favorable RME 
Unvaforable RMA 
 
 
 
 
 
Localization 
Favorable Orbital (without infiltration of 
the bone) 
Head and neck-non 
parameningeal 
Urogenital-non 
bladder/prostate 
Unfavorable Orbita with bone infiltration 
Head and neck-parameningeal 
Urogenital-bladder/prostate 
Extremities 
Others (thorax, pelvis, 
abdominal wall) 
Lymph node status N0 No involvement 
N1 Lymph nodes involved 
 
Table 2. The risk stratification for RMS according to the CWS Guidance (6).   
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Treatment 
The treatment of children suffering from RMS is multimodal and includes 
chemotherapy in conjunction with either surgery, radiation therapy or a combination 
of both, in order to maximize local tumor control.  
 
In the CWS Guidance, which is used in Germany, Austria, Switzerland, Poland, and 
Sweden, the sequence and the intensity of the treatment depend on the stage, 
localization of the tumor, tumor size, histology, age at diagnosis and are adapted to 
the risk categories.  
 
Chemotherapy 
Chemotherapy regimen in the current CWS guidance are based on the results of 
the CWS-96 trial (Literatur) and depend on the specific risk group. In general, 
patients are treated with a multidrug chemotherapy regimen including alkalators, 
alkaloids, actinomycin-D as well as platin derivates. In most cases, chemotherapy 
is applied for 3 cycles prior to local control. Chemotherapy is continued after local 
therapy for several cycles depending on the risk stratification.  
 
Radiotherapy      
Radiotherapy is an essential treatment modality for selected cases of RMS. 
Generally, it is administered after 3 cycles of induction chemotherapy. IRS stage, 
lymph node status, histology and tumor response to chemotherapy after 9 weeks of 
treatment are essential for stratification of local control.  
 
The following guidelines for RT have been proposed in the CWS guidance: 
Patients with initial complete resection (R0), no lymph node involvement and 
favorable histology should not be irradiated, while those with alveolar histology 
should receive a dose of 41.4 Gy administered in 23 fractions (6).   
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These recommendations are based on the study by Wolden et al regarding the 
benefit of radiotherapy in patients with IRS Group I and from the IRS I-III trials (25). 
The authors showed that patients in the RMA post-surgical stage I benefit from 
radiotherapy (5-year OS 82% vs 52%) while patients with favorable histology do not 
(10-year OS 95% with or without radiotherapy).  
 
Patients with grossly resected tumor but microscopic residual disease should 
receive 41.4 Gy in 23 fractions, regardless of histology (6). The recommendations 
are made in conformity with the study by Schuck et al. The authors, analyzing the 
benefit of radiotherapy in patients with RMS IRS Group II treated in the CWS trials 
81-96, showed an improved survival in the patients who received radiotherapy 
(84% vs 77%). The improvement in local control (83% vs 65%) and EFS (76% vs 
58%) was independent of histology, tumor size, tumor location and patient’s age 
(26).       
 
In patients with macroscopic residual disease and residual disease following initial 
chemotherapy, a secondary complete resection (R0, with tumor-free margins) prior 
to radiotherapy is recommended if feasible. Radiotherapy usually should follow 
secondary resection. If a complete secondary resection is not feasible after 
neoadjuvant chemotherapy  but might be possible with further tumor shrinkage, 
radiotherapy should precede surgery (6).  
 
The preferred mode of administration of radiotherapy is conventional fractionation, 
i.e. 1.8 Gy per day. In patients < 3 years of age or those with large abdominal 
fields, smaller fractions may be used. Brachytherapy may be used in cases of 
incompletely resected tumors of the vagina, perineum, bladder, prostate and orbit 
(6).  
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Prognosis  
The prognosis of patients suffering from RMS depends on the age at diagnosis, 
localization of the tumor, histology, stage, clinical group and response to therapy 
(9). Patients assigned to the low-risk group have an excellent prognosis with 5-
year event-free survival (EFS) and overall survival (OS) of 88% and 97% 
respectively (27). Patients with metastases at diagnosis (high-risk group) have the 
worst outcome with  5-year EFS and OS rates of 57% and 67%, respectively (27). 
Patients assigned to the standard-risk group have a 5-year EFS and OS of 72% 
and 95%, respectively. However, the prognosis of these tumors is poor, the 5-year 
EFS and OS rate independent of stage being 67% and 78%, respectively (28).  
The role of the surgery in the treatment of children suffering from 
RMS 
Surgery plays a key role in the treatment of children suffering from RMS as 
complete tumor resection is one of the main prognostic factors preventing local 
tumor recurrence (29). Completely resected tumors at the time of primary 
diagnosis present a lower risk of relapse and have a better post-relapse prognosis 
as reported by Dantonello et al (24). Even in patients with relapsed RMS, the 
removal of the tumor by a second-look operation seems to be essential to 
maintaining a stable remission (30).  
 
The main problem in the surgery of these tumors is the lack of a clear delimitation 
between the tumor and healthy tissue, especially in complex anatomical regions 
such the bladder, the prostate, the pelvis, and the porta hepatis. Therefore, 
mutilating surgery is sometimes necessary to acquire a complete resection in 
order to prevent local recurrence.  
 
Radiotherapy as an integral part of local control will be needed in selected cases. 
It might help to reduce tumor volumes, thus avoiding radical surgical procedures. 
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Therefore, the timing of radiotherapy has to be coordinated with surgery. However, 
the side effects of radiotherapy such as breast aplasia, impairment of respiratory 
function, potentiation of the cardiotoxic effect of actinomycin-D and adriamycin) as 
well as secondary malignancies should be considered (31).   
 
Identification of tumor margins is even more difficult in cases of tumor relapse. In 
these patients, the interpretation of imaging studies is difficult due to a poor 
discrimination between tumor tissue and scarring. Under these circumstances, 
novel diagnostic and therapeutic modalities aimed to improve the intra-operative 
visualization of the tumors and their margins are required. One such option is 
fluorescence diagnosis also known as photodynamic diagnosis (PDD) and 
photodynamic therapy (PDT). 
 
The role of photodynamic diagnosis (PDD) in the improvement of 
the intraoperative detection of the tumors 
The principle of photodynamic diagnosis (PDD) is to enhance the contrast 
between the tumor and healthy tissue by the interaction of the light of a specific 
wavelength with a photosensitive agent, which ideally should have a great affinity 
to cancer cells (32). This method has received significant interest in surgical 
oncology improving the early detection of breast, urogenital, pulmonary, and 
gastrointestinal cancers (33-37).  
 
In pediatric solid tumors, there are only very limited reports on PDD. Videoscopic 
fluorescent diagnosis of peritoneal and thoracic metastases using 5-aminolevulinic 
acid (5-ALA) was reported in a rat model of human hepatoblastoma (38). Our 
group has previously demonstrated that in vivo visualization of xenotransplanted 
pediatric RMS after transfection with red fluorescent protein is effective (39). 
Additionally, we could demonstrate in vivo cancer cell trafficking of RMS cells and 
describe different mechanisms of metastatic invasion using this technique (15).  
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 The potential clinical utility of fluorescent proteins in RMS is limited as they need 
to be bound to specific antibodies. The problem in RMS is the absence of specific 
cell surface receptors. However, Hermann et al analysed the expression of cell 
surface EGFR (epidermal growth factor receptor) on 3 RMS cell lines by flow 
cytometry and demonstrated that ERMS and ARMS exhibited a high expression of 
EGFR (40). Therefore, EGFR may function as a target for therapeutic antibodies. 
Cetuximab is a monoclonal antibody that targets the extracellular domain of 
EGFR. Thus, the labeling of this antibody with a fluorochrome may lead to the 
specific detection of the tumor based on its fluorescence. Withrow et al. 
successfully demonstrated in vivo visualization of tumor cells using cetuximab 
conjugated with indocyanine green (ICG) in a mouse model of head and neck 
cancer (41).  
 
ALA is an intermediate in hem biosynthesis in the body. In the biosynthetic 
pathway of heme, ALA is converted into protoporphyrin IX (PpIX), an endogenous 
fluorescent photosensitizer, which selectively accumulates in tumor cells due to 
changes in the activity of two enzymes: prophobilinogen deaminase (increased 
activity) and ferrochelatase (decreased activity) as shown in the Figure 1.  When 
excited by blue light, Pp IX generates red fluorescence (33, 42). 5-ALA derived Pp 
IX fluorescence has been successfully used for intraoperative visualization of 
malignant gliomas, improving the prognosis of patients (43).  Moreover, a long-
sustaining response (56 months) in a patient with non-resectable reccurence of a 
glioblastoma multiforme after treatment with interstitial photodynamic therapy 
(iPDT) was reported (44). However, this photosensitizer is rapidly bleached out 
and exposure to light is limited to short illumination periods (32). 
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Figure 1. Heme biosynthetic pathway and 5-ALA metabolism into Pp IX 
Pp IX: protoporphyrin IX; Pp III: protoporphyrin III; PBG: porphobilinogen; UPBG: 
uroporphobilinogen; CPBG:  coproporphobilinogen;  
 
Hypericin is a hydroxylated phenanthroperylenequinone derivate, isolated from 
plants of St. John´s Wort (Hypericum perforatum), a naturally occurring herb in 
Europe and Asia. It has primarily been used for the treatment of depressive 
disorders (45), but in recent years has been described for in vivo visualization of 
bladder cancer (46). Selective accumulation of hypericin in tumor cells was 
reported by several authors (47-50). Hypericin has a great photostability and a 
lower fluorescence clearance in comparison to ALA,  (46). Comparing the cellular 
uptake and photodynamic inactivation of meduloblastoma cells in vitro, after 
incubation with hypericin and 5-ALA, Ritz et al convincingly demonstrated that the 
fluorescence and phototoxicity of hypericin are superior to those determined by 5-
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ALA: 5-fold increase in fluorescence and 8-13 fold lower LD50 (Light Dose 50: the 
light dose that is required to reduce cell survival to 50% of control) (51).  
 
Photodynamic therapy (PDT), currently studied as a novel treatment approach in 
various malignancies, involves the systemic or topical administration of a 
photosensitizer followed by exposure of the tumor with light of appropriate 
wavelength. In the presence of oxygen, photoactivated sensitizers generate highly 
reactive oxygen species (ROS). The oxidative damage to various cellular 
organelles and functions induced by ROS leads to direct cytotoxicity on tumor cells 
(52). Beside its fluorescending properties, hypericin is also a very potent 
photodynamic agent and after activation with light of appropriate wave length 
(excitation 590 nm, emission 640 nm), it produces singlet oxygen efficiently 
(quantum yield of 0.73) resulting in the apoptosis of the tumor cells (53, 54). We 
previously reported the successful in vitro photodynamic therapy of RMS cells (47) 
and pediatric epithelial liver tumors (55) promoted by hypericin, but the transfer of 
this data into an in vivo setting is difficult due to the necessity of a tumor selective 
accumulation of the photosensitizer in RMS. In children this is even more difficult 
due to the accelerated metabolism and rapidly growing tissue.     
Up to now there is no data on in vivo photodynamic diagnosis and therapy using 
fluorescence laparoscopy in pediatric RMS.  
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Objectives of the study 
 
The aim of this study was to investigate the feasibility of fluorescence laparoscopy 
using different photodynamic agents in a mouse model of disseminated pediatric 
RMS. Additionally, we wanted to figure out if hypericin-induced photodynamic 
therapy on childhood alveolar RMS cells might be feasible in vivo as a novel 
promising treatment option for advanced-stage RMS. For this purpose, we tried to 
answer the following questions: 
1. It is possible to perform an in vivo detection of RMS tumors based on 
the expression of the mCherry reporter protein using fluorescence 
laparoscopy? 
2. Is the in vivo detection of RMS tumors based on their vascularization 
using fluorescence laparoscopy, after i.v. injection of ICG, possible? 
3. Is the in vivo specific detection of RMS tumors based on their surface 
antigen using fluorescent labeled Cetuximab in the setting of 
fluorescence laparoscopy feasible? 
4. Is the detection of the RMS xenotransplants possible using hypericin-
based fluorescence laparoscopy? 
5. Is in vivo hypericin-induced photodynamic therapy possible during 
laparoscopy? 
6. Is a therapeutic intervention in this system comprehensible? 
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MATERIALS AND METHODS 
Cell lines and culture conditions 
The alveolar RMS cell line Rh30 (DSMZ, Braunschweig, Germany) was used for 
this study. This cell line was obtained from a bone metastasis of a 17-year old 
young man suffering from an alveolar RMS.    
All cells were cultured in DMEM medium (GIBCO, Berlin, Germany) supplemented 
with 10% fetal calf serum, 1% L-Glu, 2.5% HEPES and antibiotics 
(Penicillin/Streptomycin, Biochrom, Berlin) in a humidified atmosphere containing 
10% carbon dioxide at 37°C. All cells were mycoplasma negative. The medium 
was changed every second day and the cells were passaged if a confluence rate 
of 80% was reached. These procedures were performed under sterile conditions in 
cabinets with laminar flow filtered air.  
Medium change 
The supernatant consisting of medium and nonviable cells was aspirated using a 
vacuum pump and Pasteur pipettes. Approximately 5 ml of warmed PBS solution 
(Biochrom, Berlin) was added and the Petri dishes were gently swirled to remove 
the cellular debris. Then the PBS solution was aspirated and 8 ml of fresh culture 
medium was added. 
Passage of the cells   
The supernatant was aspirated and the cells were washed with PBS previously 
warmed at 37°C. To detach the adherent cultures from the bottom of the plate, 2 
ml of trypsin (PAA Laboratories, Pasching, Austria) was added. After 2 minutes, 
culture medium was added in order to inhibit the activity of trypsin and to stop the 
proteolysis. The cell suspension was aspirated and centrifuged for 5 minutes at 
600 rotations /minute. After centrifugation, 4/5 of the cells were removed or divided 
into new Petri dishes. Five milliliters of fresh culture medium per Petri dish was 
added to the remaining cells.  
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Determination of the number of cells  
For determination of the number of cells, 10 µl of the cell suspension were 
dropped laterally and aspirated by the capillary force into the Neubauer counting 
chamber (Roth, Karlsruhe, Germany). Under light microscopy (40X magnification) 
4 great quadrants were counted. To determine the number of cells/ml, the cell 
number counted was divided by 4 and multiplied with the chamber factor 104. 
Based on the number of the cells/ml, the absolute number of cells could be 
determined in the cell suspension. Further, the cells were centrifuged for three 
minutes at 1300 rotations/minute, the supernatant aspirated and the desired cell 
concentration resuspended in culture medium.   
Transduction of the Rh30 cell line with mCherry reporter protein 
(mCherryLentifect®)  
The transduction of the Rh 30 cells in order to stably express the red fluorescent 
protein mCherry was carried out using the kit and the guidelines from 
GeneCopoeiaInc (mCherry Lentifect®, Rockville, U.S.A.). For the efficient 
expression of the red fluorescent protein mCherry, the lentiviral particle contains a 
CMV promoter and a puromycin cassette (Figure 2). The Rh30 cells were cultured 
in 24 well plates (Becton Dickinson, Heidelberg, Germany) until they reached 80% 
confluence. Polybren 6µg/ml (Gibco/Invitrogen, Darmstadt, Germany) was added 
in order to facilitate the penetration of the viruses into the cells. After application of 
10µl mCherryLentifect®/plate the plates were incubated for 24 hours at room 
temperature. The following day the medium was changed and the lentivirus was 
chemically neutralized. For selection, 0.3µg/ml Puromycin® (Sigma-Aldrich, 
München) was added at every medium change until drug-resistant colonies 
became visible (56). 
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Figure 2. Schematic representation of the lentiviral transfer vector that expresses the mCherry 
protein (micrograph from the manufacturer) 
Fluorochromes 
mCherry is a monomeric red fluorescent protein derived from a protein isolated 
from Discosoma sp. It is used in biotechnology as a tracer to follow the flow of 
fluids as well as a marker when labeled to molecules or cell components. It 
matures rapidly allowing it to be visualized very soon after activating transcription.  
It has a peak absortion at 587 nm and emission at 610 nm (Table 4). It is highly 
photostable and resistant to photobleaching (57) (Figure 3). Due to its high 
photostability and low molecular weight it is considered the best general-purpose 
red monomer (58). 
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              Figure 3. mCherry expressing tumor cells as seen by fluorescence microscopy 
 
 
 
 
Indocyanine green (ICG) is a tricarbocyanine dye which is internationally 
approved for use in cardiac, (micro) circulatory and liver function diagnosis (59). It 
is an ideal agent for imaging vessels as it bounds tightly to plasma proteins and 
therefore remains strictly intravascular. The excitation (600-900 nm) and emission 
(750-950 nm) profiles of ICG are in the near infra-red (NIR) wavelengths, which 
allow light penetration and imaging of vessels below a few millimeters of tissue 
(60) (Figure 4, Table 3).  
 
 
 
 
 
 
 
A A 
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Figure 4. Maximal absorption and emission spectrum of ICG. Modified from (61). 
 
 
Hypericin, a hydroxylated phenanthroperylenequinone derivate is a constituent of 
plants of the genus Hypericum perforatum (Figure 5) (54). Its affinity against 
tumor cells was demonstrated by several studies (47, 54, 55). After activation with 
light of appropriate wave length (excitation 590 nm, emission 640 nm), it produces 
singlet oxygen efficiently (quantum yield of 0.73) resulting in apoptosis of the 
tumor cells (53, 54). Hypericin is present as a constituent in Hypericum extract, 
which is clinically used as an antidepressant (45). In recent years it has been 
described for in vivo visualization of bladder cancer (62) and has been studied as 
a photodynamic agent in different tumor entities (63-68). The impressive anti-
angiogenic effects of hyepericin were also reported by several authors (66, 68) 
(see Table 3) 
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   Figure 5. a. Hypericum perforatum, the herb from which hypericin is extracted b. Chemical 
structure of Hypericin. Modified from (54).  
 
Photosensitizer Maximal absorption Maximal emission 
mCherry (57) 587 nm 610 nm 
ICG (69) 780 nm 820 nm 
Hypericin (70) 590 nm 640 nm 
 
Table 3. Maximal spectral absorption and emission of the photosensitizers used  
 
Labeling of Cetuximab with ICG 
Labeling of Cetuximab (Erbitux, Merck, Darmstadt, Germany) with ICG (DojindoEu 
GmbH, Munich, Germany) was performed as suggested by the manufacturer. To 
this purpose, the sample solution containing 200 µg Cetuximab (Erbitux, Merck, 
Darmstadt, Germany) was mixed with 100 µl WS Buffer, using a pipette, in a 
filtration tube. The solution obtained was centrifuged at 8000 rotations/minute for 
15 minutes.  
a b 
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To prepare the ICG solution, 500 µl NH2-Reactive ICG 10 µl DMSO was added 
into the NH2-Reactive ICG tube and dissolved by pipetting. Reaction Buffer (100 
µl) and NH2-Reactive ICG solution (8 µl) were added in the filtration tube, mixed by 
pipetting and then incubated at 37°C for 10 minutes. After 10 minutes, 100 µl WS 
Buffer (DojindoEu GmbH, Munich, Germany) was added and the filtration tube 
was centrifuged at 8000 rotations for 15 minutes. After centrifugation, another 
200µl WS Buffer was added and centrifugation at 8000 rotations per minute was 
performed for 15 minutes. The final step was to add 200 µl PBS to the product and 
pipette it 10 times to recover the conjugate. A final concentration of 200µg/200µl 
was obtained.      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Schematic representation of ICG-labeled Cetuximab 
 
Labeling efficiency was estimated using flow cytometry and the Odissey system 
(LI-COR Biosciences GmbH, Bad Homburg, Germany). The Odissey system is an 
imaging system, which uses infrared laser excitation resulting in decreased 
excitation light leakage, higher signal-to-noise ratio and sensitive detection of low 
abundant targets (proteins, antibodies, etc.).  
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To this purpose, Rh30 cells were incubated with labeled antibody at 0.1 to 5µg/ml 
and visualized in flow cytometry with the LSR II (BD, Heidelberg, Germany). 
Staining of adherent Rh30 cells with ICG conjugated Cetuximab was revealed by 
the Odissey system.  
Animal model 
NOD/LtSz-scid IL2Rγnull-mice were used for this study. This mouse strain was 
initially described by Schultz et al. (71). These animals have severe impairments in 
innate immunity due to the absence of the IL2Rγ gene. This gene is responsible 
for encoding the γ chain of the interleukin-2 receptor (IL2R) and plays an important 
role in growth and differentiation of T-cells, B-cells, NK-cells and monocytes. 
 
The animals were kept in pathogen-free conditions, on an autoclaved standard 
diet and given free access to sterilized water.    
Xenotransplantation of the tumor cells 
 Tumor induction was carried out using human alveolar RMS cells (Rh 30) in all 
the experiments. For xenotransplantation, the tumor cells were trypsinized as 
previously described. The cells were washed with PBS, centrifuged and then 
resuspended in 200 µl DMEM. A total number of 2×106 RMS cells were injected 
intraperitoneally in every mouse.  
 
After xenotransplantation, the mice were clinically evaluated every day and the 
weight was measured. In case of a weight loss of more than 20%, combined with 
the loss of appetite, diarrhea and apathy, the animal was sacrificed.  
Design of the animal experiments 
All animal experiments were approved by the local government ethics committee 
for animal studies (Regierungspräsidium Tübingen, K5/11) and were performed 
under sterile conditions.  
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Seventeen NOD/LtSz-scidIL2Rγnull-mice were used. In order to analyze different 
photosensitizers, the mice population was divided into 4 groups as shown in Table 
4.  
Group Fluorochrome Objective Dosage/mouse n 
1 mCherry Tumor detection based on 
stable mCherry expression  
Stable 
transduction 
5 
2 ICG Tumor detection based on 
neovascularization 
100µg/100 µl  3 
3 ICG-cetuximab Specific tumor detection 
based on EGFR 
100µg/mouse 4 
4 Hypericin Tumor detection based on 
the hypericin-uptake of the 
tumor cells 
100µg/200 µl 5 
 
 Table 4. Objectives of the examination and the dosages of the fluorochromes used 
 
In the first group, tumor induction was carried out with genetically modified Rh 30 
cells to stably express the red fluorescent protein mCherry after excitation with 
light of the appropriate wave length.  
 
In the following three groups, tumor induction was carried out using non-
transfected, non-fluorescending Rh 30 cells. The application of the fluorochromes 
was carried out in the following way: 
 
In the second group, 100µg/µl indocyanine green (ICG) was injected intravenously 
at the time point of initiation of laparoscopy. The objective was to evaluate the 
detection of the tumor based on its vascularization. Photosensitisation times (time 
interval between application of photosensitizer and light excitation) of 5 minutes 
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were chosen based on the previous experience of other authors in other studies 
(59).  
 
In the third group, in order to increase the specificity of the method, we evaluated 
the in vivo detection of the tumor cells based on its surface antigens (EGFR). We 
previously demonstrated that Cetuximab specifically binds to EGRF expressed by 
Rh 30 cells in vitro (40). Therefore, 100µg of ICG-labeled Cetuximab was 
intravenously injected 24 hours prior to laparoscopy.  
 
In the fourth group, we evaluated the detection of the tumors based on their 
hypericin uptake. Selective accumulation of hypericin in the tumor cells was 
previously reported by several authors (47, 54).  The photosensitization was 
carried out using hypericin (Merck, Darmstadt, Germany) at a concentration of 
100µg/200µl/mouse, intravenously injected 24 h prior to laparoscopy.     
 
To evaluate the effects of photodynamic activation of hypericin on tumors and 
surrounding tissue during laparoscopy, the tumors located in the porta hepatis and 
on the greater curvature of the stomach underwent excitation with blue light for 5 
minutes. The animals were kept for 4 hours in the dark to avoid photosensitivity 
and to allow the initiation of apoptosis. Tumors and livers were then collected and 
stored deep frozen to evaluate apoptosis by a terminal desoxyribosyl-transferase-
mediated dUTP nick-end labeling test (TUNEL).  
Fluorescence laparoscopy 
Equipment  
We used the Karl Storz D-Light System (Karl Storz GmbH&Co., Tuttlingen, 
Germany). Two models of this system are available, both capable of different 
illumination modes.  
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The D-Light P system has been tailored to meet the requirements of ICG 
fluorescence imaging. This system is equipped with an excitation light source 
(100W short-arc xenon lamp) and a specifically designed optical filter mounted on 
a filter wheel that can be activated using a button placed on the camera head. 
Using this button, the filter can be placed or removed, thus the excitation 
wavelength from the light source may be shifted from the conventional white light 
(WL mode) to blue light (AF mode: 380-450 nm) or near-infrared light (ICG mode: 
690-780 nm). Additionally, a long pass filter, located in the eyepiece of the 
telescope allows the passage of 790 nm and longer, which corresponds to the 
emission wavelength of the fluorochromes used. We used this system in the first 
three groups for the detection of the mCherry and ICG-determined fluorescence.  
 
The D-Light C system was created to improve the detection of different types of 
tumors based on their fluorescence after injection of a specific fluorescence agent 
and excitation with light of the appropriate wave length. This system is also 
equipped with a xenon 100 W short arc lamp with filter options for white light (WL 
mode) and fluorescence excitation (AF mode: 380-450 nm). The eyepiece of the 
telescope has integrated a long pass filter (> 520 nm) to block the reflected blue 
excitation light without blocking the red fluorescence. We used this system in the 
fourth group for the detection of hypericin-determined fluorescence. 
 
For optimal transmission of the excitation light, the systems are provided with a 
special fluid light guide. A special modified camera (Tricam SL II, Karl 
StorzGmbH&Co., Tuttlingen, Germany) was used for documentation.  The camera 
presents several features: enhanced sensitivity in the wavelength range greater 
than 600 nm, automatically and manually adjustable target integration of images in 
fluorescence mode, two independent white balances for white light and 
fluorescence and the possibility to switch the mode of illumination from the camera 
head (72). 
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Photosensitizer System Mode Excitation Emission 
mCherry 
D-Light P 
AF 380-450 nm 610 nm 
ICG/ICG-Cetux. ICG 690-780 nm LP 790 nm 
Hypericin D-Light C AF 380-450 nm 
LP > 520 
nm 
 
Table 5. Optical properties of the laparoscopic system 
 
Procedure 
Fluorescence laparoscopy was performed 3 weeks after tumor induction. All 
surgical procedures were performed under general anesthesia with Ketamin 10% 
and Xylazin 2%, 100µl/10g mouse injected intraperitoneally. After anesthesia, the 
mouse was placed in the supine position, on a heating plate. The abdominal hair 
was chemically removed using a depilatory creme (Veet, Mannheim, Germany). 
Under sterile conditions, a small incision was carried out in the lower middle 
abdomen for the placement of a 5-mm optical port. To maintain proper insufflation, 
a purse-string suture was placed around this incision. The insufflation was carried 
out with carbondioxide 0,5l/min flow and 2 mmHg pressure using a thermoflator 
(SCB Thermoflator, Karl StorzGmbH&Co., Tuttlingen, Germany). After insufflation, 
a 3-mm 0° laparoscope (Karl StorzGmbH&Co., Tuttlingen, Germany) was 
introduced in the abdominal cavity. The procedure started with the inspection of 
the abdominal cavity using white light. The tumors detected were counted and the  
location was noted (73).  
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Figure 7. Schematic representation of laparoscopic system (Storz D-Light, Karl Storz GmbH&Co., 
Tuttlingen, Germany) 
 
After laparoscopy, a laparotomy was performed and 3 tumors / mouse were 
resected using the fluorescence as guidance. After resection, the fluorescence of 
the tumor bed was documented and tumors together with the resection margins 
were histologically analyzed. At the end of the operation, the mice were sacrificed 
by administration of a lethal dose of anesthetics (73). 
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Figure 8. The abdominal cavity of the mouse, as seen during laparotomy. The arrows indicate the 
tumors  
 
In vivo photodynamic therapy 
For the evaluation of photodynamic therapy, only animals from the fourth group, in 
which the photosensitization was carried out with hypericin were suitable. In these 
mice, after laparoscopy, the tumors located on the lesser curvature of the stomach 
and in the porta hepatis were exposed to blue light (AF mode of the D-Light C 
system, Karl StorzGmbH&Co., Tuttlingen, Germany) for 5 minutes. The abdominal 
wound was closed and the mice were kept in a dark environment to avoid 
photosensitivity. After 4 hours, a laparotomy was performed and the tumors as 
mentioned previously were collected and stored in liquid nitrogen. To verify 
possibly induced apoptosis in the surrounding tissue inadvertently exposed to blue 
light during the procedure, the livers of the mice were collected and analyzed 
together with the tumors. To evaluate apoptosis induced by the photoactivation of 
hypericin, a terminal desoxyribosyl-transferase-mediated dUTP nick-end labeling 
test (TUNEL) was performed (73).  
34 
 
Evaluation of apoptosis after photodynamic therapy - TUNEL test 
For investigation of induced apoptosis in tumors and surrounding tissues Terminal 
deoxyribosyl-transferase-mediated dUTP nick-end labeling test (TUNEL) was 
performed. Therefore, 10 µm cryosections of the tissue involved were rinsed in 
PBS. The cells were fixed with Roth-Histofix solution (Roth, Munich, Germany) 
and rinsed in PBS three times. Slides were then incubated in 0.1% Triton/PBS 
(Merck, Darmstadt, Germany) on ice for 2 minutes and rinsed with PBS. For 
positive controls, cells were incubated with DNase I (Roche Diagnostics) 1:10 in 
PBS, 15 minutes at room temperature. TUNEL reaction solution (50µl/well, Roche 
Diagnostics, #1684795, Pinzberg, Germany) was added for 60 minutes at 37°C. 
For negative controls, 50µl/well of labeling solution without enzyme (Roche 
Diagnostics, #1684795) was added. Slides were rinsed in PBS for three times. For 
nuclear counterstaining, DAPI was used for 1 minute (Sigma-Aldrich, #D-9452, 
Munich, Germany, dilution 1:10 000), followed by washing in PBS three times, 
each time for 5 minutes. The slides were then mounted with mounting medium 
(Dako, Glostrup, Denmark) and analyzed by fluorescence microscopy (Zeiss 
AxioVision, Carl Zeiss Microscopy GmbH, Germany)(73).  
Histological analysis 
Paraffin embedding and paraffin sections 
To preserve tissue morphology, the specimens obtained during the surgery were 
fixed in 3.7% formalin for 24 hours. Tissues were dehydrated using ascending 
ethanol series (70%, 90% and 100% ethanol) and xylole (Xylol®, Merck, 
Darmstadt, Germany) for 60 minutes. After dehydration, the tissue was embedded 
in paraffin using the automated tissue processing system from the Department of 
Pathology of the University Hospital Tübingen and the paraffin blocks obtained 
were stored at room temperature.    
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To obtain thin paraffin sections, the block was previously cooled for 24 hours at -
20°C. Thin sections (3 µm) were performed using a microtome. The slices 
obtained were placed in a water bath at 45°C using a wet brush. The paraffin 
section was then positioned on the glass slide, transferred to a warm drying 
platform and dried at 60°C.   
Hematoxylin-eosin staining 
The paraffin sections obtained as previously described were deparaffinized using 
ethanol and xylole. After deparaffinization, the slides were stained with Mayer 
hematoxylin solution (Merck, Darmstadt, Germany) for 2 minutes and then washed 
with running tap water for 5 minutes. For counterstaining, the slides were bathed in 
eosin solution for 1 minute, then dehydrated using ethanol ascending series and 
mounted with a xylole-based medium. For histological evaluation, 10 high power 
fields per slide were used.  
Data processing 
The images obtained during laparoscopy were not processed in any way. 
Representative frames are presented. The histologic images were processed for 
brightness and contrast using the AxioVision (Carl Zeiss Microscopy GmbH, 
Germany) digital image processing software.  
Statistics 
Descriptive statistics for continuous variables are expressed as median and range. 
Significance was assumed for all results with p<0.05.  
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RESULTS 
Initially, 25 NOD/LtSz-scid IL2Rγnull mice were used for this study. Three weeks 
after tumor induction, tumor growth was observed in 22 mice. In three mice no 
tumor growth occurred. Five mice died due to tumor progression. The remaining 
17 mice represent the population used further in the study. This population was 
divided into 4 groups in order to investigate different photosensitizers. 
Group I – Detection of RMS tumors based on the expression of 
the mCherry reporter protein using fluorescence laparoscopy 
(n=5) 
The conventional laparoscopy (WL mode) revealed a total number of 32 tumors in 
all 5 animals (median 6 tumors/mouse [2-10]). Among these, 13 suspicious lesions 
(median 3 tumors/mouse [1-4]) were not fluorescending after excitation with blue 
light (AF mode) and were considered false positive. The histological examination 
of these structures revealed no RMS cells. The remaining 19 tumors in all 5 
animals (median of 3 tumors /mouse [1-7]) were visible under both conventional 
(WL mode) and blue light (AF mode) as red fluorescending tissue. These tumors 
had a median size of 4.8 mm [1.6 – 7.7] and were characterized by a prominent 
appearance as shown in the Figure 9 a, b. 
 
Additional 38 tumors in all 5 animals (median per animal: 11 tumors [range 3-20] 
p=0.026), which were not visible during conventional laparoscopy due to their 
plane morphology and small dimensions (median size 0.8 mm, [0.4 – 2.7]), could 
be detected only due to their fluorescending properties (Figure 9 c, d) during 
fluorescence laparoscopy. The histological work-up of these specimens revealed 
alveolar RMS cells and tumor-free margins.   
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   Figure 9. Appearance of the RMS tumors (arrow) located on the lesser curvature of the stomach  
as seen during  conventional (a) and fluorescence laparoscopy (b). In the fat pad near the seminal 
vesicles, several tumors (arrow) with small dimensions and plane morphology (c) were missed by 
conventional laparoscopy but were detected under blue light based on their fluorescending 
behavior (d). Modified from (73)  
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Group II – Detection of RMS tumors based on their 
neovascularization using ICG-fluorescence laparoscopy (n=3) 
In the second group, after xenotransplantation of non-transfected Rh30 cells, 20 
tumors were detected in all mice (median 6 tumors [range 5-9] during conventional 
laparoscopy (WL mode) (Figure 10 a)). During examination with blue light (ICG 
mode) no fluorescence signals could be detected and the tumors appeared as 
dark spots (Figure 10 b). However, mesenteric blood vessels were clearly 
detected in the flooding phase of ICG. The fluorescence of ICG in the vessels 
persisted for approximately 10 minutes (Figure 10 c).  
 
 
Figure 10. Tumors detected during the conventional laparoscopy (a – weighted arrow) did not 
accumulate ICG and appeared as dark areas during examination in ICG mode (b - weighted 
arrow). The mesenteric blood vessels (c – dotted arrow) were clearly seen during the flooding 
phase of ICG. Modified from (73) 
  
Group III - Specific detection of RMS tumors based on their 
surface antigens using ICG-labeled cetuximab and fluorescence 
laparoscopy (n=4) 
In this group, in order to increase the specificity of the method, ICG-Cetuximab 
was injected into the animals 24 hours prior to laparoscopy. No enhanced 
fluorescence could be detected in the tumors using the ICG mode (Figure 11 b). 
However, the ex vivo examination of the tumors using the Odissey system, 
revealed a successful binding of the ICG-labeled Cetuximab to the tumors cells as 
shown in Figure 11 c. In this group, a total number of twenty-four tumors in all 
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animals (median 6 tumors [2-10]) could be visualized during conventional 
laparoscopy (WL mode).    
 
 
   
 
Figure 11. Accumulation of ICG-labeled cetuximab in the tumors (a - arrow) did not enhance the 
fluorescence of the tumor (b – arrow) during examination with blue light. The ex vivo examination 
using the Odissey system revealed a successful binding of the ICG-labeled cetuximab to RMS 
tumor cells (c – white box). Modified from (73) 
 
Group IV – Detection of RMS tumors based on their hypericin 
uptake and using fluorescence laparoscopy (n=5) 
In this group, during conventional laparoscopy (WL mode) 28 tumors (median 4 
tumors/mouse [3-10]) were detected in all animals. Among these, 4 (median 1 
tumor/mouse [0-2]) did not exhibit fluorescence during examination with blue light 
(AF mode) and were considered false positive. The histological examination of 
these structures revealed no RMS cells.   
 
The remaining 24 tumors (median 3 tumors[ 2-10]) in all animals could be easily 
identified and differentiated from the healthy tissue due to a strong red 
fluorescence signal (Figure 12 a, b).   These tumors had a median size of  4.4 mm 
[1.6 – 13.5] and a prominent appearance. 
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 28 additional tumors in all 5 animals (median per animal: 10 tumors [7-18]) could 
be detected only during fluorescence laparoscopy based on their red fluorescence. 
They had a median size of 2.1 mm [0.5 – 11], and could not be distinguished from 
the surrounding tissue during conventional laparoscopy due to their plane 
morphology (Figure 12 c, d). The histological examination confirmed the presence 
of alveolar RMS cells in these tumors and also tumor free margins. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Aspect of RMS tumors (black arrows) located on the greater curvature of the stomach  
during conventional (a) and fluorescence laparoscopy (b - black arrows). The tumors with plane 
morphology and small dimensions localized in the lower abdomen (c - black arrow) which were 
missed by conventional laparoscopy (c), were clearly identified after administration of hypericin and 
examination in AF mode (d – white arrows). Modified from (73) 
 
a 
 
  
b 
  
 
d 
 
 
c 
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Effects of hypericin-induced photodynamic therapy 
 
The TUNEL assay revealed the induction of apoptosis in almost all tumor cells 
(Figure 13 a). Additionally, apoptosis was also detected in the few healthy liver 
cells that were inadvertently exposed to blue light during laparoscopy (Figure 13 
b) suggesting a possible damage of the liver exposed to blue light during the 
laparoscopic procedure.   
 
 
 
 
 
Figure 13. TUNEL assay of the tumors after PDT using hypericin. The majority of the tumor cells 
were apoptotic(a - green). The counterstaining with DAPI revealed nuclei (a - blue) of all cells as 
marker of apoptosis. Apoptosis was also found in a lower degree in the areas of the liver which 
were inadvertently exposed to blue light during the procedure (b - green). Modified from (73). 
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DISCUSSION 
 
Rhabdomyosarcoma is the most common soft tissue sarcoma and the third most 
common extracranial solid tumor of childhood, accounting for approximately 5% of 
all pediatric cancers (1, 4, 5). 
The treatment of RMS is multimodal, including chemotherapy in conjunction with 
surgery, radiotherapy or a combination of both, in order to maximize local tumor 
control. The cooperative clinical groups from Europe (CWS Study Group, Italian 
Cooperative Group for pediatric STS, SIOP MMT Committee) and North America 
(STSC of the Children’s Oncology Group) developed risk stratification systems to 
tailor treatment to need of patients. 
It is due to the activity of these cooperative study trials that the survival of children 
suffering from RMS has improved dramatically over the last 30 years, from 25% in 
the early seventies to 70% nowadays. In the CWS experience, the low, standard 
and high risk group patients showed an EFS rate of 88%, 72% and 57%, and an 
OS rate of 97%, 95% and 67%, respectively (6). In the Italian Cooperative Group 
RMS-88 study, the overall 5-year EFS and OS were 65% and 74%, respectively 
(74), while in the MMT-89 study of the International Society of Pediatric Oncology 
the 5-year EFS and OS reached 57% and 71% (75). On the other side of the 
Atlantic, in the IRS Studies of the Children’s Oncology Group the 5-year survival 
improved significantly from 55% on IRS-I and IRS-II studies to more than 70% on 
the IRS-III and IRS IV protocols (76).      
However, the prognosis of the patients with high-risk disease remains poor with a 
3-year event free survival (EFS) of less than 30% according to IRS studies (77). In 
the CWS-96 study, the survival of the patients with high-risk disease was better (5-
year EFS 57% and OS 67%) but still remains poor (27).  
Effective local control of the tumor is essential for the survival of patients with 
RMS. Thus, the main goal of the surgical treatment of RMS is the microscopically 
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complete tumor resection with avoidance of mutilating procedures. Due to a lack of 
clear delimitation between tumors and healthy tissue, especially in complex 
anatomical regions such as the pelvis, this objective is often difficult to accomplish. 
Thus, mutilating surgical procedures are sometimes required in order to achieve a 
complete tumor resection in order to prevent local recurrence.    
Therefore, novel diagnostic and therapeutic modalities such as photodynamic 
diagnosis and therapy aiming to improve the intra-operative visualization of the 
tumors and their margins are required. 
Based on the promising clinical results obtained in the field of urology in the 
detection of carcinoma in situ or small papillary tumors of the bladder (36), 
fluorescence diagnosis has also received significant interest in surgical oncology 
improving the early detection of breast, urogenital, pulmonary, and gastrointestinal 
tumors (33-37). 
However, there are only few reports in the literature regarding fluorescence 
diagnosis for pediatric solid tumors. Successful tumor visualization using 
fluorescence laparoscopy with 5-ALA was reported in a rat model of 
xenotransplanted human hepatoblastoma (38). However, 5-ALA is known to 
rapidly bleach out and exposure to light is limited to short illumination periods. 
Additionally, the penetration into the tissue is low. Therefore, only superficial 
tumors can be detected. Moreover, it was not specified if complete tumor resection 
under fluorescence guidance was feasible in this model. 
Our group has previously demonstrated that in vivo visualization of 
xenotransplanted pediatric RMS after transfection with red fluorescent protein 
(DsRed2) was effective (39). However, the potential clinical utility of 
fluorescending proteins in RMS is limited as they need to be bound to specific 
antibodies, which seems to be inapplicable in these tumors due to the absence of 
specific cell surface receptors. However, fluorescending agents represent an 
alternative for in vivo tumor visualization. In the present study, we used our mouse 
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model of disseminated pediatric RMS to evaluate the feasibility of fluorescence 
laparoscopy using different photosensitizers (mCherry, ICG and hypericin). This 
animal model resembles very well pediatric RMS in terms of organ invasion, 
intraperitoneal tumor spread, and difficulty to discriminate between tumor and 
surrounding tissue. The tumors exhibited strong fluorescence signals with an 
excellent contrast between the tumor margins and surrounding tissues using 
mCherry and hypericin. Therefore, both the identification of the tumors, based on 
their fluorescending behaviour, and their resection using fluorescence guidance 
could be carried out easily. In these groups, fluorescence laparoscopy resulted in 
a 1.6 fold increased tumor detection rate with a specificity of 100%. Comparable 
results were reported by other authors with Pp IX and 5-ALA fluorescence in a rat 
model of ovarian cancer (78) and disseminated colon carcinoma, respectively (79).  
Indocyanine green (ICG) is a fluorescent agent currently used in cardiac, micro 
(circulatory) and liver function diagnosis (59). Together with methylene blue, they 
are the only near-infrared fluorophores that are registered with the Food and Drug 
Administration (FDA) and the European Medicines Agency (EMA) for clinical use. 
It has been shown that ICG passively accumulates in hepatocellular carcinoma 
and in non-cancerous hepatic parenchyma compressed by the colorectal liver 
metastases when intravenously administered between 1 and 14 days prior surgery 
(80). Thus, intraoperative fluorescence imaging techniques using ICG were 
developed and surgeons began to use them clinically to delineate cancers in the 
liver during open and laparoscopic hepatectomy (80-82). However, the major 
limitation of ICG fluorescence imaging is the inability to detect deeply located 
tumors. In the series of Kudo et al. none of the lesions located 8 mm or more from 
the liver capsule could be identified using ICG fluorescence (81).    
In our model, using ICG, despite the good vascularisation of pediatric RMS, no 
fluorescence signals could be detected during ICG fluorescence laparoscopy. A 
possible reason might be the small dimensions of the tumors and their supplying 
blood vessels. During the histological examination of these tumors, we additionally 
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observed the presence of more vascular mimicry in contrast to “real” blood 
vessels. Vascular mimicry, also referred as vasculogenic mimicry, represents 
matrix-rich, non-endothelial-lined, vasculogenic-like channel networks responsible 
for the perfusion of certain types of tumors including alveolar RMS (83). Probably, 
the matrix-rich wall of these vascular-like channels might be responsible for the 
poor fluorescence signals obtained.      
The chemical structure of ICG allows it to be conjugated with tumor specific 
antibodies (84). In order to improve the retention of ICG in RMS tumors, we 
labeled ICG to cetuximab, as our study group recently reported the successful 
binding of Cetuximab to RMS cells due to high expression of EGFR (40). We 
thought that targeting an antigen with higher density on the tumor cells may also 
enhance the fluorescence intensity leading to a better discrimination of the tumors. 
However, the results were not as expected. No enhancement of the ICG-
fluorescence could be observed. Nevertheless, the ex vivo examination of the 
tumors using a laser-based system revealed a successful accumulation of the 
ICG-labeled cetuximab into the tumors. Similarly, Withrow and colleagues reported 
successful visualization of tumor cells, based on their binding to ICG labeled 
cetuximab and using a spectromicroscope in a mouse model of head and neck 
cancer (41). Therefore, the achieved density of fluorochrome-conjugated 
antibodies to tumor cells was not sufficient for the laparoscopic detection as the 3 
mm laparoscope has been not currently optimized in NIR. 
 
Using the Storz D-Light system (Karl Storz GmbH&Co., Tuttlingen, Germany), we 
could show that fluorescence laparoscopy is feasible and usable in our animal 
model. The laparoscopic procedure using the 3 mm laparoscope was well 
tolerated by the mice and no surgery-related death occurred. The fluorescence 
diagnosis was carried out without any difficulties as it could be easily switched 
between the different examination modes. However, the intensity of the 
fluorescence signal emitted by the tumors located between the intestinal loops or 
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between the stomach and the spleen was hampered to some extent probably due 
to autofluorescence of the nutrition or absorption of the excitation light by these 
structures. Therefore, for an adequate exposure of the fluorescending tumors, the 
mobilization of these organs was necessary. A laser light source, resulting in a 
decreased excitation light leakage and higher signal-to-noise-ratio or an optical 
instrument having a better resolution may improve the detection of these tumors.   
 
We find that this system has two major advantages. First of all this system can be 
also adapted for conventional open surgical approaches. Due to the small 
dimensions of the mice, the resection of the tumors was carried out by a 
laparotomy using fluorescence guidance. A clear identification of the tumor 
margins based on the red fluorescence of the tumors was possible in this setting 
and the complete resection of the tumors (macroscopically and microscopically) 
was carried out without any difficulties. However, in humans, the operative field is 
larger compared to the mouse. Therefore, the amount of light delivered by the 
small light source of the endoscope may be insufficient for appropriate excitation 
and consequently the fluorescence signal may be weak. However, this impairment 
may be overcome by using an exoscopic video camera (VITOM®, Karl Storz 
GmbH&Co., Tuttlingen, Germany) which provides an external view of the 
operative field with a two fold magnification. VITOM® is a specially designed 
scope that is attached to a high definition digital camera and displayed on a HD 
video monitor. It is used in neurosurgery as an alternative to the operating 
microscope (85).   
The second major advantage of the system is that fluorescence laparoscopy can 
be combined with PDT at the same time for the local therapy of remnant 
microscopic tumors.   
Photodynamic therapy involves the systemic or topical administration of a 
photosensitizer resulting in a selective accumulation in the cancer cells. Excitation 
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with light of the appropriate wave length results in generation of a highly reactive 
oxygen species leading to tumor cell apoptosis. There are many reports 
demonstrating the effectiveness of this method as a novel treatment option for 
various malignancies (47, 48, 50, 70, 86). The main photosensitizers used are 5-
ALA and hypericin.  
Hypericin is a hydroxylated phenantroperylenequinone derivate, isolated from 
plants of St. John’s Wort (Hypericum perforatum) (54). It has primarly been used 
for the treatment of depressive disorders (45, 64). Hypericin has been described 
for in vivo visualization of bladder cancer (62) and has been studied as a 
photodynamic agent in different tumor entities (63, 64, 66, 68). Some of these 
studies revealed also impressive anti-angiogenic effects (66, 68). Interestingly, 
some authors reported anti-metastatic and anti-angiogenic effects of hypericin 
even in the dark (87, 88). Ritz demonstrated even that hypericin has a higher 
phototoxicity and fluorescence compared with 5 ALA, for photodynamic 
inactivation of medulloblastoma cells (51). Thus, hypericin seems to be a better 
photodynamic agent compared with 5-ALA.    
There is a lack of reports in the literature about PDT in RMS. In our previous 
investigations we demonstrated that in vitro photoactivation of hypericin led to 
apoptosis of rhabdomyosarcoma and epithelial liver tumor cells (47, 55). Our 
present results demonstrate that hypericin-induced photodynamic therapy on 
childhood rhabdomyosarcoma is also possible in vivo as PDT with hypericin 
resulted in induction of apoptosis in the tumor samples. The TUNEL test was 
positive in almost all tumor cells 4 hours after induction of PDT. These findings 
show that hypericin specifically accumulates in RMS cells in vivo. To our 
knowledge, this is the first report in the literature, which demonstrates that PDT 
with hypericin is also possible in vivo in pediatric RMS (73).   
Although hypericin uptake is thought to be tumor specific (47), few apoptotic 
bodies were observed also in the hepatic tissue inadvertently exposed to blue light 
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during laparoscopy. Therefore, the protection of the tissue with high proliferative 
activity (e.g. liver in children) during the procedure with an opaque sheet seems to 
be necessary. 
Complications after photodynamic therapy were reported by other authors. De 
Laney et al. encountered three small bowel perforations after PDT with 2.5 mg/kg 
dihematoporphirin ethers (DHE) and light dose of 3J/cm2 in a phase I study of 
debulking surgery for disseminated intraperitoneal tumors. In one patient, further 
increase of the light dose used for PDT determined a gastric perforation and 
pleural effusion requiring thoracocentesis (89). Regarding hypericin, animal 
studies in mice showed no severe side effects of the drug if the animals were kept 
in the dark (54, 90). Moreover, hypericin is already clinically used in different tumor 
entities such as bladder carcinoma and glioblastoma without severe side effects 
(62, 91).  
One of the most important side effects of  hypericin PDT is hypericism, which is a 
severe photodermatitis observed in grazing animals and cause by the UV light 
exposure after ingestion of St John’s Wort (92). Animal hypericism ranges from 
erythema of the skin exposed to UV light to extensive rashes with vesiculation, 
edema and fever to behavioral changes, seizures and death. In humans, recent 
pharmacokinetic studies suggest that the phototoxic threshold level of hypericin is 
not reached with dosages used for the oral treatment of depression (900 - 3600 
mg of hypericin extract, equivalent of 2.8 mg - 11.25 mg hypericin plus 
pseudohypericin) (93). However, preparations containing hypericin which are used 
as an antidepressant are largerly unregulated and contain varying amounts of the 
drug (94). While studying the antiretroviral effects of hypericin on HIV infected 
patients, Gulik et al reported that all patients treated with hypericin experienced 
phototoxicity if the dosage was higher than 0.25 mg/kg twice weekly, administered 
intravenously. The toxic reaction was an erythematous rash associated with 
painful dysesthesias that involved areas exposed to light (94). The reaction 
resolved after discontinuation of the therapy. However, the doses used for 
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intraoperative visualization and PDT are considerably lower (0.1 mg/kg) (91, 95), 
therefore major side effects of hypericin should not be expected. Ritz et al. 
studying the intraoperative visualization of malignant glioma after injection of 
hypericin reported no side effects or phototoxic reactions after intravenous 
administration of 0.1mg/kg hypericin (91). St John’s Wort preparations may cause 
drug interactions through the induction of the cytochrome P450 enzymes resulting 
in the increased metabolism of the drugs such as digoxin (96), theophylline or 
cyclosporine (97). This leads to decreased plasma concentration and clinical 
effects of these drugs (92).    
The indirect effects of hypericin-induced photodynamic therapy have also been 
shown to contribute to tumor destruction. Necrosis of the tumor due to vascular 
compromise when high intravascular concentrations of hypericin were present at 
the time of photoactivation was demonstrated by Chen et al in a tumor model of 
radiation-induced fibrosarcoma (RIF-1). The immune system also seems to play a 
role in tumor destruction by activation of inflammatory cells following PDT (98), 
since less tumor damage occurred in mice treated with cyclosporin A prior to PDT 
as described by Eastin et al (99). In our model, due to low vascularisation of the 
tumors and highly immunosuppressed mice, these aspects of PDT could not be 
assessed. 
As a possible translational approach, integration of hypericin in RMS surgery can 
be achieved without major changes. Injection of hypericin prior to surgery may 
allow a better detection of the tumor margins to facilitate microscopically complete 
tumor resections. Ritz et al recently reported the successful fluorescence-guided 
resection of recurrent malignant gliomas using an injectable solution of hypericin 
(91).  PDT of incomplete resection margins may also improve the outcome of the 
patients due to the destruction of microscopical residuals. Intraoperative PDT 
could either be carried out during laparoscopy or during open tumor resections 
with specific filters in the OR lighting system.  
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While studying the differences in metabolic pathways in rhabdomyosarcoma Rh 30 
cells and human primary myocites in vitro using stable isotope tracing methods, 
Fan et al observed that in Rh 30 cells, glycolysis, Kreb’s cycle pentose phosphate 
pathway as well as nucleotide biosynthesis were enhanced compared with normal 
myocites, in order to meet the demand for accelerated growth. They also showed 
that the mitochondria of  Rh 30 cells are active both in Kreb’s cycle and respiratory 
electron transport and postulated that these processes may be responsible for the 
transformation of primary myocites into malignant cells (100). Electrochemical 
studies demonstrated that hypericin is capable of either accepting or donating 
electrons, thus functioning as both oxidizing and reducing agent, which may 
facilitate activities in the dark as well. Several studies revealed the anti-metastatic 
and anti-angiogenic effects of hypericin in the dark (87, 88).  
Finally, we conclude that fluorescence laparoscopy is a promising novel tool for in 
vivo diagnosis and photodynamic therapy of childhood rhabdomyosarcoma. The 
first steps for a translation into the clinic were taken by developing and using 
injectable hypericin (91, 101). Therefore, a clinical trial will now be initiated in 
children suffering from advanced-stage RMS.   
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SUMMARY 
Rhabdomyosarcoma is the most common soft tissue sarcoma in children. The 
multimodal treatment resulted in an increased survival rate of patients with 
localized disease. However, the prognosis of children in advanced stages of the 
disease remains poor. Local control of the tumor is essential for the survival of 
these patients. Surgery plays a key role in the local treatment of RMS. The main 
problem remains the lack of clear identification of tumor margins, especially in 
complex anatomical regions. This sometimes leads to mutilating surgical 
procedures to acquire a R0 resection in order to prevent local tumor recurrence. 
To overcome this major problem, novel diagnostic and therapeutic approaches 
aiming to improve the intraoperative tumor visualization are necessary.  
Photodynamic diagnosis represents a novel technique aiming to improve the 
intraoperative tumor detection. The principle of PDD is based on the accumulation 
of a photosensitizer in the tumor cells. The interaction of light of specific 
wavelength with the tumor causes the fluorescence of the photosensitizer, thus 
resulting in easy identification of the tumor. Using this technique, promising results 
were obtained in surgical oncology regarding early detection of various 
malignancies. The most commonly used substances to this purpose are 5-ALA 
(with its derivatives) and hypericin. There are many reports which demonstrate the 
superiority of hypericin to ALA regarding photostability.  
In the present study, fluorescence laparoscopy using hypericin resulted in a 1.6 
increased tumor detection rate with a specificity of 100%. The tumors exhibited 
strong fluorescence signals and an excellent contrast between tumor margins and 
healthy tissue. Thus, the identification and resection of the tumors under 
fluorescence guidance could be carried out easily. This is the first report in the 
literature on in vivo PDD in pediatric RMS. 
Besides its fluorescending properties, hypericin is also known as a very potent 
photodynamic agent. After activation with light of appropriate wavelength it 
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produces singlet oxygen efficiently, resulting in apoptosis of the tumor cells. 
Successful in vitro hypericin-induced PDT of RMS cells was previously reported by 
our study group. In the present study we demonstrated that hypericin-induced PDT 
is also possible in vivo. Photodynamic therapy after photosensitization with 
hypericin resulted in the induction of apoptosis in almost all tumor cells. This 
suggests that hypericin specifically accumulates in RMS cells in vivo. This is the 
first report on in vivo hypericin-induced PDT in pediatric RMS. 
The integration of hypericin in RMS surgery can be achieved without major 
difficulties. The first step for translation into the clinic was done by developing 
injectable hypericin. Moreover, hypericin is already clinically used in different 
tumor entities without major side effects. The injection of hypericin prior to surgery 
may allow a better detection of tumor margins, possibly resulting in R0 tumor 
resections. Furthermore, fluorescence laparoscopy can be combined with PDT at 
the same time for the local therapy of incomplete resection margins. This may 
improve the outcome of the patients due to destruction of microscopic residuals. 
Intraoperative PDD and PDT are possible either during laparoscopy or in the 
setting of open surgery using specific filters in the OR lighting system.  
In conclusion, fluorescence laparoscopy is a promising novel tool for in vivo PDD 
and PDT of pediatric RMS. Therefore, a clinical trial will now be initiated in children 
suffering from advanced-stage RMS.    
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ZUSAMMENFASSUNG 
Das Rhabdomyosarkom ist das häufigste Weichteilsarkom im Kindesalter. Die 
multimodale Therapie führte zu einer erhöhten Überlebensrate des Patienten mit 
lokalisierter Erkrankung. Die Prognose im fortgeschrittenen Tumorstadium ist 
jedoch bis heute sehr schlecht. Die Detektion und die vollständige Entfernung der 
Tumoren sind für eine erfolgreiche Therapie essentiell. Deshalb spielt die 
Chirurgie in der lokalen Behandlung dieser Tumoren  eine wichtige Rolle. Das 
Hauptproblem in der Chirurgie des Rhabdomyosarkoms ist, dass die 
Resektionsgrenzen nicht eindeutig identifiziert werden können. Daraus resultiert, 
dass in manchen Fällen die Tumoren nur durch eine mutilierende Operation 
reseziert werden können. Dennoch verbleibt ein Restrisiko mikroskopische 
Tumorreste zu belassen. Die genaue intraoperative Detektion von Tumoren und 
vor allem ihrer Grenzen in anatomisch komplexen Regionen durch optische 
Hilfsmittel wäre ein wichtiger Schritt in der Tumorchirurgie.  
Die photodynamische Diagnostik (PDD) oder Fluoreszenzdiagnostik ist ein relativ 
neues Verfahren für Verbesserung der intraoperativen Tumordetektion. Diese 
Methode basiert auf die Akkumulation von photodynamisch aktiven Substanzen 
(Photosensibilisatoren) in den Tumorzellen. Daraus resultiert eine Verbesserung 
des optischen Kontrastes zwischen Tumor und den umgebenden Gewebe. 
Hypericin ist eine hierfür am häufigsten verwendeten Substanzen. Bisher 
existieren keine wissenschaftliche Untersuchungen zur in vivo 
Fluoreszenzdiagnostik mit Hypericin bei kindlichen RMS. In der vorliegenden 
Studie konnte beobachtet werden, dass die Fluoreszenzlaparoskopie mit 
Hypericin zu einer 1.6 erhöhten Tumoridentifikationsrate bei einer Spezifizität von 
100% geführt hat. Die Identifizierung und die Resektion der Tumoren konnte 
problemlos aufgrund deren Fluoreszenzenz durchgeführt werden. Dies ist der 
erste Bericht in der Literatur über die in vivo Fluoreszenzlaparoskopie bei 
kindlichen RMS.  
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Neben der positiven Eigenschaften von Hypericin in der photodynamischen 
Diagnostik, kann es auch für die photodynamische Therapie eingesetzt werden. 
Hierbei kommt es durch die Anregung mit Licht einer bestimmten Wellenlänge zur 
Bildung von Sauerstoffradikalen. In dieser Studie haben wir beobachtet, dass die 
intraoperative PDT mit Hypericin zur Induktion der Apoptose in fast alle 
Tumorzellen geführt hat. Unsere Beobachtung legen daher nahe, dass die 
Hypericin sich spezifisch in RMS Zellen in vivo akkumuliert.  
Der Einsatz von Hypericin in der Klinik kann ohne große Veränderungen erreicht 
werden. Der erste Schritt für den Einsatz in der Klinik wurde durch die Entwicklung 
einer Hypericin-Injektionslösung realisiert. Darüber hinaus wird Hypericin bereits 
klinisch bei verschiedenen Tumorentitäten verwendet. Die 
Fluoreszenzlaparoskopie kann zusammen mit der PDT kombiniert werden. Nach 
der Aufnahme von Hypericin in den RMS Zellen könnte das OP-Licht zur 
Visualisierung der Tumorgrenzen und zur Induktion der PDT verwendet werden. 
Intraoperative PDD und PDT sind entweder während der Laparoskopie oder in 
Rahmen eines offen chirurgischen Eingriffs möglich. 
Zusammenfassend ist die Floreszenzlaparoskopie eine sehr versprechende 
Methode für die intraoperative Tumordetektion. Die PDT mit Hypericin stellt eine 
potentielle neue Therapieoption zur Behandlung des kindlichen RMS dar, welche 
sowohl eine bessere intraoperative Tumoridentifizierung als auch eine 
intraoperative Therapieoption darstellen könnte. Deshalb wird nun eine klinische 
Studie bei kindlichen mit fortgeschrittenem Tumorsstadium initiiert werden. 
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